152 related articles for article (PubMed ID: 35315085)
21. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
22. Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing.
Maag JLV; Fisher OM; Levert-Mignon A; Kaczorowski DC; Thomas ML; Hussey DJ; Watson DI; Wettstein A; Bobryshev YV; Edwards M; Dinger ME; Lord RV
Mol Cancer Res; 2017 Nov; 15(11):1558-1569. PubMed ID: 28751461
[TBL] [Abstract][Full Text] [Related]
23. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
[TBL] [Abstract][Full Text] [Related]
24. Current Status of Chemoprevention in Barrett's Esophagus.
Moayyedi P; El-Serag HB
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
[TBL] [Abstract][Full Text] [Related]
25. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
26. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
[TBL] [Abstract][Full Text] [Related]
27. Gastroesophageal reflux disease and Barrett's esophagus.
Falk GW
Endoscopy; 2001 Feb; 33(2):109-18. PubMed ID: 11272213
[TBL] [Abstract][Full Text] [Related]
28. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
[TBL] [Abstract][Full Text] [Related]
29. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo.
Obszynska JA; Atherfold PA; Nanji M; Glancy D; Santander S; Graham TA; Otto WR; West K; Harrison RF; Jankowski JA
Gut; 2010 Feb; 59(2):156-63. PubMed ID: 19651631
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
31.
Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
[No Abstract] [Full Text] [Related]
32. Advances in Barrett's esophagus and esophageal adenocarcinoma.
Shaheen NJ
Gastroenterology; 2005 May; 128(6):1554-66. PubMed ID: 15887151
[TBL] [Abstract][Full Text] [Related]
33. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Richardson P; El-Serag HB
Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100
[TBL] [Abstract][Full Text] [Related]
34. High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions.
Phipps SM; Garry CE; Kamal S; Johnson JD; Gilmer J; Long A; Kelleher D; Duggan SP
Cell Mol Gastroenterol Hepatol; 2020; 10(3):601-622. PubMed ID: 32416156
[TBL] [Abstract][Full Text] [Related]
35. [Argon plasma coagulation in Barrett's esophagus].
Nomura T; Yamashita K; Miyashita M; Tajiri T
Nihon Rinsho; 2005 Aug; 63(8):1458-62. PubMed ID: 16101240
[TBL] [Abstract][Full Text] [Related]
36. Acidic digestion in a teleost: postprandial and circadian pattern of gastric pH, pepsin activity, and pepsinogen and proton pump mRNAs expression.
Yúfera M; Moyano FJ; Astola A; Pousão-Ferreira P; Martínez-Rodríguez G
PLoS One; 2012; 7(3):e33687. PubMed ID: 22448266
[TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori eradication treatment and the risk of Barrett's esophagus and esophageal adenocarcinoma.
Doorakkers E; Lagergren J; Santoni G; Engstrand L; Brusselaers N
Helicobacter; 2020 Jun; 25(3):e12688. PubMed ID: 32175626
[TBL] [Abstract][Full Text] [Related]
38. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
Akın H; Aydın Y
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
[TBL] [Abstract][Full Text] [Related]
39. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
40. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
